Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development.
about
Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance?Prevention of Surgical Site Infections and Biofilms: Pharmacokinetics of Subcutaneous Cefazolin and Metronidazole in a Tumescent Lidocaine Solution.Antibiotic resistance: Alternative approachesHow to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient.Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome SequencingSearching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patienThe effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium.Identifying "at-risk" patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections.Delivering precision antimicrobial therapy through closed-loop control systems.Population pharmacokinetics and dosing optimisation of ceftazidime in infants.MIC-based dose adjustment: facts and fables.Optimising drug dosing in patients receiving extracorporeal membrane oxygenation.Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion
P2860
Q28552950-65811BB3-8557-4994-8CE5-E265EE62B230Q30854769-72CFEACA-B071-44DA-8C31-350C8259D822Q33872306-DE247087-C7D0-4A8C-83C4-86299E618F04Q36275612-032C5596-53C0-41E2-A0A9-2321E69F6BD9Q36760879-F5680133-EDEC-4BEE-B6F0-25E7A8E4835DQ37188148-7AA5E239-F480-482E-8124-5F3E9E95AD5CQ38740720-9880C7DE-D251-44D2-88E1-EDF6DC88F14EQ38798373-DFAB6050-E19A-40ED-ADDA-04B3765FCFE3Q38867438-58834670-6422-4E94-8419-2E72D899507CQ40470332-5F71B7C6-6656-4284-B55C-C5C71CEA2202Q41718334-FD49A306-B600-45DD-B588-2EDEA3FC4D9FQ45840280-C5639F72-B26D-4E3C-9AC4-690F07B3D446Q47276911-990F4176-617A-42C4-A15F-DC7A18D87AE3Q47645055-DD607C68-8C5D-4C34-8734-816A0A120654Q50027512-F9042775-EECF-46CF-817E-D0E3B6968728Q55393633-B134F6A4-3A77-4E60-9622-E854949358DEQ57815074-60171262-2BA2-4119-B4AD-8527E3095033
P2860
Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Applying pharmacokinetic/pharm ...... ducing resistance development.
@en
type
label
Applying pharmacokinetic/pharm ...... ducing resistance development.
@en
prefLabel
Applying pharmacokinetic/pharm ...... ducing resistance development.
@en
P50
P356
P1476
Applying pharmacokinetic/pharm ...... ducing resistance development.
@en
P2093
Johan W Mouton
P304
P356
10.1055/S-0034-1398490
P577
2015-02-02T00:00:00Z